1. Search Result
Search Result
Results for "

gut disease

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

17

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N10617

    Antibiotic Bacterial Infection
    Hygromycin A is a Borrelia burgdorferi-selective antibiotic. Hygromycin A is a spirochete-specific antibacterial that is conducive to gut health. Hygromycin A can be used for Lyme disease research .
    Hygromycin A
  • HY-116688

    Bacterial Others
    2-Hydroxy-4-(methylthio)butyric acid is a dietary essential amino acid which is converted to Methionine (HY-13694) by 2-hydroxy acid dehydrogenase and 2-hydroxy acid oxidase. 2-Hydroxy-4-(methylthio)butyric acid is promising for research of gut disease .
    2-Hydroxy-4-(methylthio)butyric acid
  • HY-128442

    Phenyl hydrogen sulfate

    Endogenous Metabolite Metabolic Disease
    Phenyl sulfate is an orally active gut microbiota-derived metabolite. Phenyl sulfate induces albuminuria and podocyte damage in experimental models of diabetes. Phenyl sulfate can be used as a disease marker and future therapeutic target in diabetic kidney disease .
    Phenyl sulfate
  • HY-106539

    LDLR Metabolic Disease Cancer
    Colesevelam (hydrochloride) is a bile acid sequestrant that bind bile acids in the gut. Colesevelam (hydrochloride) inhibits bile acid reabsorption, leading to increased bile acid synthesis and reduced cholesterol levels in patients with cholestatic pruritus and Crohn’s disease.
    Colesevelam hydrochloride
  • HY-112071

    Adrenergic Receptor Cardiovascular Disease
    Prenalterol is a selective β1-adrenergic receptor agonist. Prenalterol has no effect on gut smooth muscle contractile activity. Prenalterol can be used for researching cardiovascular disease .
    Prenalterol
  • HY-W010516

    2-Methylpentanoic acid

    Endogenous Metabolite Metabolic Disease
    2-Methylvaleric acid is a branched short-chain fatty acid (SCFA) produced by the metabolism of branched-chain amino acids by gut microbes. 2-Methylvaleric acid can be used as a potential biomarker for metabolic diseases such as type 2 diabetes, and its content is significantly reduced in the feces of diabetic mice. 2-Methylvaleric acid may regulate host energy metabolism and inflammatory response through G protein-coupled receptors (GPCRs) or histone deacetylase (HDAC) inhibition. 2-Methylvaleric acid can be used to study gut microbe-host interactions and metabolic diseases as a fecal biomarker[1][2].
    2-Methylvaleric acid
  • HY-141521
    Amelenodor
    1 Publications Verification

    NX-13

    NOD-like Receptor (NLR) Inflammation/Immunology
    NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis .
    Amelenodor
  • HY-116688R

    Others Others
    2-Hydroxy-4-(methylthio)butyric acid (Standard) is the analytical standard of 2-Hydroxy-4-(methylthio)butyric acid. This product is intended for research and analytical applications. 2-Hydroxy-4-(methylthio)butyric acid is a dietary essential amino acid which is converted to Methionine (HY-13694) by 2-hydroxy acid dehydrogenase and 2-hydroxy acid oxidase. 2-Hydroxy-4-(methylthio)butyric acid is promising for research of gut disease .
    2-Hydroxy-4-(methylthio)butyric acid (Standard)
  • HY-128442R

    Endogenous Metabolite Metabolic Disease
    Phenyl sulfate (Standard) is the analytical standard of Phenyl sulfate. This product is intended for research and analytical applications. Phenyl sulfate is an orally active gut microbiota-derived metabolite. Phenyl sulfate induces albuminuria and podocyte damage in experimental models of diabetes. Phenyl sulfate can be used as a disease marker and future therapeutic target in diabetic kidney disease .
    Phenyl sulfate (Standard)
  • HY-W010516R

    2-Methylpentanoic acid (Standard)

    Reference Standards Endogenous Metabolite Metabolic Disease
    2-Methylvaleric acid (Standard) is the analytical standard of 2-Methylvaleric acid. This product is intended for research and analytical applications. 2-Methylvaleric acid is a branched short-chain fatty acid (SCFA) produced by the metabolism of branched-chain amino acids by gut microbes. 2-Methylvaleric acid can be used as a potential biomarker for metabolic diseases such as type 2 diabetes, and its content is significantly reduced in the feces of diabetic mice. 2-Methylvaleric acid may regulate host energy metabolism and inflammatory response through G protein-coupled receptors (GPCRs) or histone deacetylase (HDAC) inhibition. 2-Methylvaleric acid can be used to study gut microbe-host interactions and metabolic diseases as a fecal biomarker[1][2].
    2-Methylvaleric acid (Standard)
  • HY-12820
    Sibofimloc
    3 Publications Verification

    Antibiotic-202

    Bacterial Antibiotic Infection
    Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD) .
    Sibofimloc
  • HY-N0299

    Endogenous Metabolite Apoptosis Metabolic Disease Inflammation/Immunology
    Stachyose hydrate is an orally active prebiotic that enhances the growth and activity of beneficial bacteria. Stachyose hydrate has hypoglycemic effects and can improve inflammation by regulating gut microbiota. In addition, Stachyose hydrate can induce plant cell apoptosis (Apoptosis). Stachyose hydrate can be used in research on inflammation, gastrointestinal diseases, and agriculture .
    Stachyose hydrate
  • HY-W012734
    L-Pipecolic acid
    1 Publications Verification

    H-HoPro-OH

    Endogenous Metabolite Metabolic Disease
    L-Pipecolic acid (H-HoPro-OH) is an oral active metabolite of Lysine and can accumulate in the bodily fluids of infants with autosomal inherited diseases, such as Zellweger syndrome and neonatal adrenal insufficiency. L-Pipecolic acid can promote muscle cell health and growth by enhancing protein synthesis, and plays a role in promoting gut health. L-Pipecolic acid holds promise for research in the fields of metabolic disorders, muscle growth disorders, and intestinal diseases .
    L-Pipecolic acid
  • HY-N0469
    L-Lysine
    Maximum Cited Publications
    7 Publications Verification

    Endogenous Metabolite Virus Protease HSV Infection Metabolic Disease Inflammation/Immunology
    L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation .
    L-Lysine
  • HY-12820R

    Antibiotic-202 (Standard)

    Reference Standards Bacterial Antibiotic Infection
    Sibofimloc (Standard) is the analytical standard of Sibofimloc. This product is intended for research and analytical applications. Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD)[1][2].
    Sibofimloc (Standard)
  • HY-14441

    5-HT Receptor Neurological Disease
    ML 10302 is a potent agonist 5-HT4 receptor with Ki of 1.07 nM. 5-Hydroxytryptamine (5-HT4) receptor agonists stimulate gut motility through cholinergic pathways. ML10302 induces significant prokinesia both in the small bowel and colon through activation of cholinergic pathways. ML 10302 also has the potential for the research of neurology diseases .
    ML 10302
  • HY-W012734R

    H-HoPro-OH (Standard)

    Reference Standards Endogenous Metabolite Metabolic Disease
    L-Pipecolic acid (Standard) is an analytical standard of L-Pipecolic acid. This product is used for research and analytical applications. L-Pipecolic acid (H-HoPro-OH) is an oral active metabolite of Lysine and can accumulate in the bodily fluids of infants with autosomal inherited diseases, such as Zellweger syndrome and neonatal adrenal insufficiency. L-Pipecolic acid can promote muscle cell health and growth by enhancing protein synthesis, and plays a role in promoting gut health. L-Pipecolic acid holds promise for research in the fields of metabolic disorders, muscle growth disorders, and intestinal diseases .
    L-Pipecolic acid (Standard)
  • HY-175222

    Toll-like Receptor (TLR) NF-κB Caspase TNF Receptor Interleukin Related Metabolic Disease Inflammation/Immunology
    GlcNAc-MurNAc, a disaccharide, is a TLR4 agonist with a Kd of 383 μM for murine TLR4. GlcNAc-MurNAc directly binds to TLR4 and activates its downstream NF-κB and IRF pathways. GlcNAc-MurNAc improves Dextran sulfate sodium salt (DSS) (HY-116282C)-induced colitis in mice through a TLR4-dependent mechanism. GlcNAc-MurNAc can be used for the study of inflammatory bowel disease .
    GlcNAc-MurNAc
  • HY-P9984
    Etrolizumab
    2 Publications Verification

    rhuMAb Beta7; RG7413; PRO145223

    Integrin Cancer
    Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
    Etrolizumab
  • HY-W674241

    Endogenous Metabolite Cardiovascular Disease
    4-Ethylphenyl sulfate is a gut microbial metabolite. 4-Ethylphenyl sulfate is also a protein-bound uremic toxin, a xenobiotic substrate, and causes endothelial dysfunction .
    4-Ethylphenyl sulfate
  • HY-W674241A

    Endogenous Metabolite Cardiovascular Disease
    4-Ethylphenyl sulfate sodium is a gut microbial metabolite. 4-Ethylphenyl sulfate sodium is also a protein-bound uremic toxin, a xenobiotic substrate, and causes endothelial dysfunction .
    4-Ethylphenyl sulfate sodium
  • HY-W015229R

    Indole-3-propionic acid (Standard); 3-IPA (Standard)

    Reference Standards Endogenous Metabolite Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease
    3-Indolepropionic acid (Standard) is the analytical standard of 3-Indolepropionic acid. This product is intended for research and analytical applications. 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease. In Vitro: 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease . 3-Indolepropionic acid is a more potent scavenger of hydroxyl radicals than melatonin. Similar to melatonin but unlike other antioxidants, 3-Indolepropionic acid scavenges radicals without subsequently generating reactive and pro-oxidant intermediate compounds . It is also suggested that indolepropionic acid, a gut microbiota-produced metabolite, is a potential biomarker for the development of type 2 diabetes (T2D) that may mediate its protective effect by preservation of β-cell function .
    3-Indolepropionic acid (Standard)
  • HY-N7635

    β-D-Glucopyranosyl oleanolate

    NO Synthase COX Interleukin Related Claudin p38 MAPK Akt PI3K Inflammation/Immunology
    Oleanolic acid 28-O-β-D-glucopyranoside (β-D-Glucopyranosyl oleanolate) is an orally active pentacyclic triterpenoid compound. Oleanolic acid 28-O-β-D-glucopyranoside has anti-inflammatory effects. In ulcerative colitis models, Oleanolic acid 28-O-β-D-glucopyranoside can inhibit the inflammatory response, enhance the intestinal epithelial barrier function, and modulate the gut microbiota. Its mechanism of action is related to the PI3K-AKT and MAPK signaling pathways. Oleanolic acid 28-O-β-D-glucopyranoside can be used in the research of diseases such as colitis .
    Oleanolic acid 28-O-β-D-glucopyranoside
  • HY-W013636C
    2-Ketoglutaric acid potassium
    5 Publications Verification

    Alpha-Ketoglutaric acid potassium

    Tyrosinase Endogenous Metabolite TNF Receptor Neurological Disease Metabolic Disease
    2-Ketoglutaric acid (Alpha-Ketoglutaric acid) (potassium) is an intermediate in the production of ATP or GTP in the Krebs cycle. 2-Ketoglutaric acid potassium is a reversible and orally active inhibitor of tyrosinase with an IC50 value of 15 mM. 2-Ketoglutaric acid potassium also acts as the major carbon skeleton for nitrogen-assimilatory reactions. 2-Ketoglutaric acid potassium significantly suppresses abnormal intestinal permeability, delocalization of tight junction proteins from the intestinal cells, expression of TNFα in vitro and in vivo. 2-Ketoglutaric acid potassium directly binds to TAK1, and inhibits the TRAF6-TAK1 interaction. 2-Ketoglutaric acid potassium also alleviates inflammatory bowel disease (IBD) symptoms and gut microbiota dysbiosis, evident by the improvements in the intestine length .
    2-Ketoglutaric acid potassium
  • HY-N0515

    PPAR NF-κB Calcium Channel Reactive Oxygen Species (ROS) ERK Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Ophiopogonin D can be isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside. Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca 2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D can inhibit isteoclastic differentiation in RAW264.7 cells. Ophiopogonin D has protective effect as an antioxidant in H2O2-induced endothelial injury. Ophiopogonin D blocks ERK signaling cascades. Ophiopogonin D alleviates high-fat diet-induced metabolic syndrome and changes the structure of gut microbiota in mice. Ophiopogonin D has been used against inflammatory, metabolic and cardiovascular diseases .
    Ophiopogonin D
  • HY-N0515R

    Reference Standards PPAR NF-κB Calcium Channel ERK Reactive Oxygen Species (ROS) Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Ophiopogonin D (Standard) is the analytical standard of Ophiopogonin D. This product is intended for research and analytical applications. Ophiopogonin D can be isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside. Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D can inhibit isteoclastic differentiation in RAW264.7 cells. Ophiopogonin D has protective effect as an antioxidant in H2O2-induced endothelial injury. Ophiopogonin D blocks ERK signaling cascades. Ophiopogonin D alleviates high-fat diet-induced metabolic syndrome and changes the structure of gut microbiota in mice. Ophiopogonin D has been used against inflammatory, metabolic and cardiovascular diseases .
    Ophiopogonin D (Standard)
  • HY-N0469R

    Reference Standards Endogenous Metabolite Virus Protease HSV Infection Metabolic Disease Inflammation/Immunology
    L-Lysine (Standard) is the analytical standard of L-Lysine. This product is intended for research and analytical applications. L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation . IC50 & Target:L-lysine (150 mg/kg) promotes, but not initiates, bladder cancer. The administration of L-lysine to rats submitted to colovesical cystoplasty accelerates the development of transitional metaplasia of the intestinal epithelium .
    L-lysine (10 mg/kg) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity . In Vivo:L-lysine (10?mg/kg, p.o., pre-treated or post-treated, administration duration 15 days) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity in acute pancreatitis mice model . L-lysine (5 or 10?mg/kg, p.o., 45 days) ameliorates sepsis-induced acute lung injury in a lipopolysaccharide (HY-D1056)-induced mouse model .
    L-Lysine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: